<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887156</url>
  </required_header>
  <id_info>
    <org_study_id>K180304J</org_study_id>
    <nct_id>NCT03887156</nct_id>
  </id_info>
  <brief_title>Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft</brief_title>
  <acronym>Predictor2</acronym>
  <official_title>Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SATT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SNC Graft Versus Host Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axonal-Biostatem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CERBA laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to validate an in vitro diagnosis medical device to predict grade II to IV aGVHD&#xD;
      after a cell graft&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Graft Versus Host Disease (aGVHD) is the most frequent complication in allogeneic&#xD;
      Hematopoietic Stem Cell Transplantation (allo-HSCT). It affects up to 50% patients, among&#xD;
      whom 15% to 25% develop severe forms, often lethal, yet impossible to predict even for donors&#xD;
      with a Human Leukocyte Antigene (HLA) 10/10 compatibility. Global Overall Survival (OS) after&#xD;
      transplantation is 40% to 60% only due to post transplant severe complications. There is a&#xD;
      major medical need for a technology that would predict the risk of aGVHD and would allow the&#xD;
      selection of a favourable donor among multiple Human Leukocyte Antigene (HLA)10/10 compatible&#xD;
      donors.&#xD;
&#xD;
      MT. Rubio and M. Bouillié at Pr Olivier Hermine's lab previously reported that enhanced early&#xD;
      post-transplant invariant Natural Killer T (iNKT) cells reconstitution from donor cells was&#xD;
      correlated to reduced risk of aGVHD, without impairment of the Graft Versus Leukemia (GVL)&#xD;
      effect. They subsequently demonstrated that the expansion of donors CD4neg invariant Natural&#xD;
      Killer T (iNKT) cells subpopulation was predictive of a reduced risk of aGVHD, and developed&#xD;
      a method for predicting this risk based on the expansion factor of CD4neg invariant Natural&#xD;
      Killer T (iNKT) cells in the peripheral blood stem cell (PBSC) graft. This invariant Natural&#xD;
      Killer T (iNKT) cells functional test reaches its optimal predictive capacity with 94%&#xD;
      sensitivity and 100% specificity in allo-HSCT performed with Human Leukocyte Antigene (HLA)&#xD;
      10/10 matched peripheral blood stem cell (PBSC) grafts for non-progressive hematological&#xD;
      malignant diseases, in complete response, which represent the majority of the indications of&#xD;
      allogeneic HSCT. Similar predictive value was also observed when the test was performed from&#xD;
      donor's peripheral blood before G-CSF mobilization. It was not associated with an increased&#xD;
      risk of relapse. This test could therefore allow to easily selecting the best donor if&#xD;
      different siblings or unrelated donors are available before PBSC allo-HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">March 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of aGVHD of grade II to IV observed for the recipients</measure>
    <time_frame>3 month after allograft performance</time_frame>
    <description>To predict the risk of acute GVHD. Number of aGVHD of grade II to IV observed for the recipients in the 3 months after the graft and results of the Predictor test, before graft, on their own donor's blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of hospitalization or medical consultation, exams, concomitant treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of medical consultations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of concomitant treatments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Lymphoma in Remission</condition>
  <condition>Non-progressive Myeloproliferative Syndrome</condition>
  <condition>Myelodysplasia With Stable Blasts is Cell Number and &lt; 10% of Blastocysts</condition>
  <condition>Acute Leukemia Biphenotypic in Remission</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test</intervention_name>
    <description>Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PATIENT :&#xD;
&#xD;
               -  Age between 18 and 65 years ( included )&#xD;
&#xD;
               -  Being candidate to a graft of peripheral hematopoietic stem cells , according the&#xD;
                  following criteria :&#xD;
&#xD;
          -  HLA compatibility 10 / 10 with the selected donor&#xD;
&#xD;
          -  Malignant haematological disorder as described below :&#xD;
&#xD;
               -  Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia ( ALL) in 1st or 2d&#xD;
                  complete remission&#xD;
&#xD;
               -  Aggressive lymphoma in complete remission&#xD;
&#xD;
               -  Non - progressive myeloproliferative syndrome ,&#xD;
&#xD;
               -  Myelodysplasia with stable blasts is cell number and &lt; 10 % of blastocysts,&#xD;
&#xD;
               -  Acute leukemia biphenotypic in 1st or 2d complete remission&#xD;
&#xD;
          -  Sequential graft conditioning, myeloablative or with a reduced intensity, both may&#xD;
             include ATG&#xD;
&#xD;
          -  Classical scheme for immunosuppression decrease ( from day 90 to day 180 ) • Not being&#xD;
             opposed to medical data collection DONOR&#xD;
&#xD;
          -  Adult ( ≥ 18 year old) up to the maximum authorized by each National Transplantation&#xD;
             Authority&#xD;
&#xD;
          -  Being a patient's sibling or registered in the Bone Marrow Donors Worldwide registry&#xD;
             or a national registry&#xD;
&#xD;
          -  Being candidate to a Peripheral Blood Stem Cells donation with a Human Leucocyt&#xD;
             Antigen (HLA) 10 / 10 compatibility with the recipient ,&#xD;
&#xD;
          -  Signed and dated informed consent ( in accordance with local regulation of the country&#xD;
             in which the observation is performed )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in a clinical trial, if interventional on the prophylaxis treatment (&#xD;
             not on the prophylaxis ) of GVHD, in the 30 days prior to the inclusion and during the&#xD;
             Predictor 2 study ,&#xD;
&#xD;
          -  Being placed under legal supervision ,&#xD;
&#xD;
          -  Presenting any impossibility to fulfil the study requirements, due to geographical,&#xD;
             social or physical reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of adult hematology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick VACHER</last_name>
    <phone>+33 1 44 84 17 30</phone>
    <email>yannick.vacher@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Lou CAMUT</last_name>
    <phone>+33 1 56 38 21 77</phone>
    <email>mlcamut@axonal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Z.N.A. Stuivenberg Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri BREEMS</last_name>
      <phone>0032 3 217 73 97</phone>
      <email>dimitri.breems@zna.be</email>
    </contact>
    <investigator>
      <last_name>Ka Lung WU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikki GRANACHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom EYCKMANS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves BEGUIN, Pr</last_name>
      <phone>003243667201</phone>
      <email>yves.beguin@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Evelyne WILLENS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric BARON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie SERVAIS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.Z. Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke VERLINDEN, Dr</last_name>
      <phone>0032 478 27 86 24</phone>
      <email>anke.verlinden@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie JORIS, Dr</last_name>
      <phone>03 22 45 59 20</phone>
      <email>joris.magalie@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie FRANCOIS, Dr</last_name>
      <phone>02.41.35.44.75</phone>
      <email>sylvie.francois@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyacinthe Atchroué JOHNSON-ANSAH, Dr</last_name>
      <phone>02 31 27 20 20</phone>
      <email>johnsonansah-a@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Valère MALFUSON, Pr</last_name>
      <phone>01.41.46.63.07</phone>
      <email>jvmalf@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemal RICHARD, Dr</last_name>
      <phone>04 73 75 00 65</phone>
      <email>rlemal@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuyten</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud JACCARD, Dr</last_name>
      <phone>05 55 05 66 52</phone>
      <email>arnaud.jaccard@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CHEVALLIER, Dr</last_name>
      <phone>02.40.08.32.69</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Simon ROHRLICH, Dr</last_name>
      <phone>04 92 03 58 41</phone>
      <email>rohrlich.ps@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitiè-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie NGUYEN-QUOC, Pr</last_name>
      <phone>01 42 16 28 25</phone>
      <email>stephanie.nguyen-quoc@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HERMINE, Pr</last_name>
      <phone>01.44.49.52.82</phone>
      <email>ohermine@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen BOTELLA GARCIA, Dr</last_name>
      <phone>05 57 65 65 11</phone>
      <email>carmen.botella-garcia@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha MAILLARD, Dr</last_name>
      <phone>05.49.44.43.07</phone>
      <email>natacha.maillard@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BERNARD, Dr</last_name>
      <phone>02 99 28 43 21</phone>
      <email>marc.bernard@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>L'Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie CHALAYER, Dr</last_name>
      <phone>04 77 91 70 60</phone>
      <email>emilie.chamayer@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne HUYNH, Dr</last_name>
      <phone>05 31 15 63 54</phone>
      <email>huynh.anne@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Thérèse RUBIO</last_name>
      <phone>03 83 15 32 82</phone>
      <email>mt_rubio@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donor Site-Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael STADLER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donor Site - Koln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rubio MT, Bouillié M, Bouazza N, Coman T, Trebeden-Nègre H, Gomez A, Suarez F, Sibon D, Brignier A, Paubelle E, Nguyen-Khoc S, Cavazzana M, Lantz O, Mohty M, Urien S, Hermine O. Pre-transplant donor CD4(-) invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. Leukemia. 2017 Apr;31(4):903-912. doi: 10.1038/leu.2016.281. Epub 2016 Oct 14.</citation>
    <PMID>27740636</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

